Table 1.
Patient characteristics by hypernatremia progression status (N = 180).
| Characteristics | All n = 180 |
Non-Progressors n = 163 |
Progressors n = 17 |
|---|---|---|---|
| Demographics | |||
| Age, median (IQR), years | 81 (69–86) | 80 (67–86) | 84 (75–87) |
| Male sex, n (%) | 109 (60.6) | 98 (60.1) | 11 (64.7) |
| Residential care, n (%) | 55 (30.6) | 49 (30.1) | 6 (35.3) |
| Comorbidities | |||
| Diabetes mellitus, n (%) | 46 (25.6) | 41 (25.2) | 5 (29.4) |
| Functional disability, n (%) | 10 (5.6) | 9 (5.5) | 1 (5.9) |
| Dementia, n (%) | 33 (18.3) | 31 (19.0) | 2 (11.8) |
| Intensive care encounter, n (%) | 81 (45.0) | 75 (46.0) | 6 (35.3) |
| Chronic kidney disease 1 | |||
| No/Stage 1 (eGFR>90), n (%) | 40 (22.3) | 40 (24.7) | 0 (0) |
| Stage 2 (eGFR 60-89), n (%) | 48 (26.7) | 44 (27.0) | 4 (23.5) |
| Stage 3 (eGFR 30-59), n (%) | 59 (33.0) | 54 (33.1) | 5 (29.4) |
| Stage 4/5 (eGFR<30), n (%) | 33 (18.3) | 25 (15.3) | 8 (47.1) |
| Diuretic use | |||
| Duration, mean (SD), days | 2.2 (2.4) | 2.3 (2.5) | 1.4 (1.9) |
| Any diuretic 2, n (%) | 108 (60.0) | 98 (60.1) | 10 (58.8) |
| Intravenous diuretic, n (%) | 85 (47.2) | 75 (46.0) | 10 (58.8) |
| Oral diuretic, n (%) | 55 (30.6) | 52 (31.9) | 3 (17.7) |
1 eGFR based on CKD-EPI equation, in ml/min/1.73 m2. 2 Oral or intravenous diuretic. Abbreviations: IQR, interquartile range; eGFR, estimated glomerular filtration rate; SD, standard deviation.